MARKET

AVTX

AVTX

Avalo Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.3193
-0.0007
-0.22%
After Hours: 0.3225 +0.0032 +1.00% 17:59 05/27 EDT
OPEN
0.3200
PREV CLOSE
0.3200
HIGH
0.3284
LOW
0.3000
VOLUME
194.90K
TURNOVER
0
52 WEEK HIGH
3.700
52 WEEK LOW
0.2019
MARKET CAP
36.02M
P/E (TTM)
-0.4463
1D
5D
1M
3M
1Y
5Y
MindMed Appoints Schond L. Greenway As CFO
Mind Medicine Inc. (NASDAQ: MNMD), (NEO:MMED), a clinical stage bio-pharmaceutical company developing novel products to treat brain health disorders, appointed Schond L. Greenway as CFO.
Benzinga · 4d ago
Mind Medicine Names Schond Greenway as CFO
MT Newswires · 4d ago
Avalo begins dosing in mid-stage study of AVTX-002 for non-eosinophilic asthma
Avalo Therapeutics (NASDAQ:AVTX) said the first patient was dosed in a mid stage study of AVTX-002 to treat non-eosinophilic asthma (NEA). The phase 2 trial, dubbed PEAK, will enroll ~80 patients and
Seekingalpha · 05/18 13:49
BRIEF-Avalo Therapeutics Says First Patient Dosed in the Phase 2 Trial of AVTX-002 for Treatment of Non-Eosinophilic Asthma
reuters.com · 05/18 11:49
Avalo Therapeutics Announces First Patient Dosed in the Phase 2 PEAK Trial of AVTX-002 for the Treatment of Non-Eosinophilic Asthma (NEA)
Topline results expected 4Q2022WAYNE, Pa. and ROCKVILLE, Md., May 18, 2022 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), announced that the first patient has been dosed in the company’s Phase 2 PEAK (A Phase 2, Randomized, Double-Blind, Plac...
GlobeNewswire · 05/18 11:30
Avalo Therapeutics Doses First Patient in Phase 2 Trial of Asthma Treatment Candidate
MT Newswires · 05/18 09:11
Avalo to Present at the H.C. Wainwright Global Life Sciences Conference
WAYNE, Pa. and ROCKVILLE, Md., May 17, 2022 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced today that Garry A. Neil, M.D., President and Chief Executive Officer, will present virtually at the H.C. Wainwright Global Life Sciences Conf...
GlobeNewswire · 05/17 11:30
--RBC Halves Price Target on Avalo Therapeutics to $2 From $4, Noting 'Early Stage Risk With Minimal Safeguards,' Keeps Outperform-Speculative Risk Rating
MT Newswires · 05/06 08:10
More
No Data
Learn about the latest financial forecast of AVTX. Analyze the recent business situations of Avalo Therapeutics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

20.00%Strong Buy
60.00%Buy
20.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average AVTX stock price target is 3.550 with a high estimate of 7.00 and a low estimate of 0.7500.
High7.00
Average3.550
Low0.7500
Current 0.3193
EPS
Actual
Estimate
-0.16-0.12-0.08-0.04
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 87
Institutional Holdings: 78.00M
% Owned: 69.16%
Shares Outstanding: 112.79M
TypeInstitutionsShares
Increased
12
3.09M
New
9
154.88K
Decreased
28
2.93M
Sold Out
14
2.61M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.72%
Pharmaceuticals & Medical Research
+1.28%
Key Executives
Non-Executive Chairman/Independent Director
Steven Boyd
President/Chief Executive Officer
Garry Neil
Chief Financial Officer
Christopher Sullivan
Treasurer
Schond Greenway
Other
Stephen Smolinski
Director
Joseph Miller
Independent Director
June Almenoff
Independent Director
Mitchell Chan
Independent Director
Gilla Kaplan
Independent Director
Keith Maher
Independent Director
Magnus Persson
No Data
No Data
About AVTX
Avalo Therapeutics, Inc., formerly Cerecor, Inc., is a clinical-stage biopharmaceutical company. The Company discovers, develops, and commercializes targeted therapeutics for patients with clinical need in immunology, immuno-oncology, and rare genetic diseases. Its pipeline consists of product candidates include AVTX-002, AVTX-007, AVTX-006 and AVTX 800 programs. Its AVTX-002 is an Anti-LIGHT mAb targeting immune-inflammatory diseases including acute respiratory distress syndrome (ARDS) and moderate-to-severe inflammatory bowel disease. Its AVTX-007 is an Anti-IL-18 mAb targeting immuno-oncology and immune-inflammatory diseases including multiple myeloma and Still’s disease. Its AVTX-006 is a dual mTORc1/c2 inhibitor targeting lymphatic malformations. Its AVTX 800 programs include AVTX-801, AVTX-802 and AVTX-803. Its AVTX 800 programs is a therapeutic doses of monosaccharide therapies for congenital disorders of glycosylation (CDGs).

Webull offers kinds of Avalo Therapeutics Inc stock information, including NASDAQ:AVTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AVTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AVTX stock methods without spending real money on the virtual paper trading platform.